Feasibility of Intratumoral Administration With <scp>EPHB4</scp>‐<scp>CAR</scp>‐T Cells for the Treatment of Oral Squamous Cell Carcinoma
Yusuke Ito(National Cancer Center Hospital East), Tetsuya Nakatsura(Unknown)
Cited by 2
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|299
HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL
|International Journal of Cancer|2008|92
Proliferation Potential-Related Protein, an Ideal Esophageal Cancer Antigen for Immunotherapy, Identified Using Complementary DNA Microarray Analysis
|Clinical Cancer Research|2004|67
The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy
|International Journal of Cancer|2009|40
Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
|Oncology Reports|2011|32